Intestinal Permeability, Irritable Bowel Syndrome with Constipation, and the Role of Sodium-Hydrogen Exchanger Isoform 3 (NHE3)

被引:0
|
作者
Lacy, Brian E. [1 ]
Rosenbaum, David [2 ]
Edelstein, Susan [2 ]
Kozuka, Kenji [2 ]
Williams, Laura A. [2 ]
Kunkel, David C. [3 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Davis Bldg,4500 San Pablo Rd, Jacksonville, FL 32224 USA
[2] Ardelyx Inc, Waltham, MA USA
[3] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA USA
来源
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY | 2024年 / 17卷
关键词
tenapanor; abdominal pain; leaky gut; gut permeability; IBS-C; tight junction protein; transepithelial resistance; PREVALENCE; INFLAMMATION; MANAGEMENT; GUIDELINE; TENAPANOR; SYMPTOMS; HABIT; PAIN;
D O I
10.2147/CEG.S455101
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Increased intestinal permeability has been identified as one of the many pathophysiological factors associated with the development of irritable bowel syndrome (IBS), a common disorder of gut-brain interaction. The layer of epithelial cells that lines the intestine is permeable to a limited degree, and the amount of paracellular permeability is tightly controlled to enable the absorption of ions, nutrients, and water from the lumen. Increased intestinal permeability to macromolecules can be triggered by a variety of insults, including infections, toxins from food poisoning, or allergens, which in turn cause an inflammatory response and are associated with abdominal pain in patients with IBS. This review article discusses increased intestinal permeability in IBS, focusing on IBS with constipation (IBS-C) through the lens of a patient case with a reported prior diagnosis of "leaky gut syndrome" upon initial contact with a gastrointestinal specialist. We review advantages and disadvantages of several methods of measuring intestinal permeability in patients and discuss when measuring intestinal permeability is appropriate in the therapeutic journey of patients with IBS-C. Furthermore, we discuss a possible mechanism of restoring the intestinal barrier to its healthy state through altering intracellular pH by inhibiting sodium-hydrogen exchanger isoform 3 (NHE3). Tenapanor is a minimally absorbed, small-molecule inhibitor of NHE3 that has been approved by the US Food and Drug Administration for the treatment of IBS-C in adults. Preclinical studies showed that tenapanor may restore the intestinal barrier in IBS-C by affecting the conformation of tight junction proteins via NHE3 inhibition to block the paracellular transport of macromolecules from the intestinal lumen. Testing for increased permeability in patients with IBS-C who experience abdominal pain may help inform the choice of therapeutics and alter patients' misconceptions about "leaky gut syndrome".
引用
收藏
页码:173 / 183
页数:11
相关论文
共 14 条
  • [11] Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
    Chey, William D.
    Lembo, Anthony J.
    Rosenbaum, David P.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 (02) : 281 - 293
  • [12] Expression and clinical significance of 5-HT and 5-HT3R in the intestinal mucosa of patient with diarrhea-type irritable bowel syndrome
    Fu, Rui
    Chen, Mingxian
    Chen, Yu
    Mao, Guoqun
    Liu, Saiyue
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (04) : 3077 - 3082
  • [13] Increased Immunoendocrine Cells in Intestinal Mucosa of Postinfectious Irritable Bowel Syndrome Patients 3 Years after Acute Shigella Infection - An Observation in a Small Case Control Study
    Kim, Hee Sun
    Lim, Jung Hyun
    Park, Hyojin
    Lee, Sang In
    YONSEI MEDICAL JOURNAL, 2010, 51 (01) : 45 - 51
  • [14] Baizhu shaoyao decoction restores the intestinal barrier and brain-gut axis balance to alleviate diarrhea-predominant irritable bowel syndrome via FoxO1/FoxO3a
    Wei, Yuanyuan
    Fan, Yimeng
    Huang, Sijuan
    Lv, Jianyu
    Zhang, Yannan
    Hao, Zhihui
    PHYTOMEDICINE, 2024, 122